Platinum Doublet

Phase 2Small molecule

Regeneron

Platinum Doublet is one of 16 small molecule programs targeting Resectable NSCLC. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Resectable NSCLCActive, not recruiting

ImmunochemotherapyRecruiting

Resectable NSCLCPhase 2

Active, not recruiting

ImmunochemotherapyPhase 2

Recruiting

Competition

Competitive Landscape

11 competitors in Immunochemotherapy

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

1 2

Immunotherapy

Bristol-Myers Squibb

Phase 3

3 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 4

Tuoyi

SSun Yat-sen University

Phase 2

1 5

PD-1 Inhibitor

Johnson & Johnson

Phase 2

1 6

Paclitaxel-Albumin

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 2

1 7

Pd-1inhibitor

SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

2 8

R-IDARAM Plus Intrathecal Chemotherapy

NNavy General Hospital, Beijing

Phase 3

2 9

Adebrelimab Combined With DOS

TTang-Du Hospital

Phase 2

1 10

Platinum Doublet

Regeneron

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Autoimmune

NCT03816345

Q2 2030

Phase 2Active, not recruiting

Non-Small Cell Lung Carcinoma

NCT05500092

Phase 2Recruiting

Immunochemotherapy

NCT06977074

Phase 2Active, not recruiting

Resectable NSCLC

NCT03916627

Clinical

Trials by Indication[1]

Immunochemotherapy1 trial

PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC

Recruiting·SSun Yat-sen University·Phase 2·NCT06977074·83 enrolled

Resectable NSCLC1 trial

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT03916627·65 enrolled

Non-Small Cell Lung Carcinoma1 trial

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Active, not recruiting·MMontefiore Medical Center·Phase 2·NCT05500092·17 enrolled

Autoimmune1 trial

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03816345·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Platinum Doublet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Platinum Doublet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Platinum Doublet. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Regeneron

Platinum Doublet

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2030

Trials by Indication[1]

Immunochemotherapy1 trial

Resectable NSCLC1 trial

Non-Small Cell Lung Carcinoma1 trial

Autoimmune1 trial

References

Drug Info

Quick Facts

Related News